Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.91 USD
-0.02 (-1.04%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $1.90 -0.01 (-0.52%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Brokerage Reports
Lexicon Pharmaceuticals, Inc. [LXRX]
Reports for Purchase
Showing records 381 - 393 ( 393 total )
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals -Q2 2012 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials Highlight Near-Term Catalysts Including Phase 2 LX4211 Data Release in Mid-2012. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of February 12
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pioneers Get the Arrows: We Believe LX4211 Will Have Smoother Sailing With the FDA Than Dapagliflozin. Reiterate OUTPERFORM and $3 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2a LX2931/Rheumatoid Arthritis Data Presented at ACR Confirms Safety
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials Slightly Better Than Consensus. Telotristat Etiprate (LX1032) Near-Term Partnership Could Be Value- Driver
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mechanistic Results at EASD Strengthen Its Profile for Diabetes and Cardiovascular Disease
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials In-Line. Telotristat Etiprate (LX1032) Showed Efficacy Signals In Phase 2a.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials Not Material In Our View. We Anticipate Clinical Catalyst In Q3.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Lexicon Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage of LXRX With an OUTPERFORM Rating and Fair Value of $3. Multiple Shots on Goal Reduces Pipeline Risk, in our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L